The binding mode of cladocoran A to the human group IIA phospholipase A(2)

Chembiochem. 2011 Nov 25;12(17):2686-91. doi: 10.1002/cbic.201100478. Epub 2011 Sep 27.

Abstract

The molecular basis for human group IIA phospholipase A(2) inactivation by the marine natural product cladocoran A (CLD A) has been studied in order to elucidate its relevant anti-inflammatory properties. Indeed, secretory phospholipases A(2) are well-known to be implicated in the pathogenesis of inflammation, such as rheumatoid arthritis, septic shock, psoriasis and asthma, thus the understanding of their inactivation mechanism could be useful for the development of new chemical classes of selective inhibitors. Our results, collected by a combination of biochemical approaches, advanced mass spectrometry and molecular modeling, suggest a competitive inhibition mechanism guided by a noncovalent molecular recognition event, and disclose the key role of the CLD A γ-hydroxybutenolide ring in the chelation of the catalytic calcium ion inside the enzyme active site. Moreover, CLD A is able to react selectively with Ser82, although this covalent event seems to play a secondary role in terms of enzyme inhibition.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 4-Butyrolactone / analogs & derivatives*
  • 4-Butyrolactone / chemistry
  • 4-Butyrolactone / metabolism
  • Anti-Inflammatory Agents / chemistry
  • Anti-Inflammatory Agents / metabolism
  • Binding Sites
  • Calcium / chemistry
  • Catalytic Domain
  • Humans
  • Models, Molecular
  • Phospholipase A2 Inhibitors
  • Phospholipases A2 / metabolism*
  • Protein Binding
  • Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

Substances

  • Anti-Inflammatory Agents
  • Phospholipase A2 Inhibitors
  • cladocoran A
  • Phospholipases A2
  • 4-Butyrolactone
  • Calcium